J. Wade

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results.

R. Schilsky, A. Benson, R. Goldberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

J. Armitage, James R. Anderson, M. Somerfield, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

M. Kris, G. Demetri, D. Cella, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy.

J. Szer, H. Prince, D. Joshua, 2010 .

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

R. Bose, H. Rugo, D. Tripathy, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.